Classement en actions
#28269
Syntara Limited is a clinical-stage biopharmaceutical company dedicated to... Syntara Limited is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies by targeting extracellular matrix dysfunction, primarily through amine oxidase chemistry. Headquartered in Frenchs Forest, Australia, the company's research pipeline focuses on blood cancers as well as a range of inflammatory and fibrotic disorders. Its leading investigational compound, amsulostat, is currently in Phase 1c/2 clinical trials for the treatment of myelofibrosis, a bone marrow cancer, and is also being evaluated for myelodysplastic syndrome. Beyond this, Syntara is advancing several other promising drug candidates. These include a suite of topical pan-LOX inhibitors: SNT-9465, which is undergoing Phase 1a/b study for hypertrophic scars, and SNT-6302, designed for keloid scars. Furthermore, SNT-4728 is in development to manage sleep disorders and to potentially slow the progression of neurodegenerative conditions by mitigating neuroinflammation. The company's broader therapeutic ambitions extend to various fibrotic and inflammatory diseases such as kidney fibrosis, MASH (metabolic dysfunction-associated steatohepatitis), pulmonary fibrosis, and cardiac fibrosis. Incorporated in 1998, the company was formerly known as Pharmaxis Ltd before adopting the name Syntara Limited in December 2023.
Prix de l'action
$0.0183374
Capitalisation boursière
$27.51M
Changement (1 jour)
0.00%
Échange Syntara Limited (SNT)
Revenus pour Syntara Limited (SNT)
Revenus en Aug 2026 TTM : 0
Selon les derniers rapports financiers de Syntara Limited, le chiffre d'affaires actuel de l'entreprise (TTM) est de 0. En 2026, l'entreprise a réalisé un chiffre d'affaires de 0 égal à le chiffre d'affaires de l'année 2026, qui était de 0. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Syntara Limited de 2026 à 2026
Revenus à la fin de chaque année
| Année |
Revenus |
Changez |
|
Pas assez de données pour les dates fournies. |
Revenus d’entreprises similaires ou concurrentes
| Entreprise |
Revenus |
Différence de revenus |
Pays |
|
|
- |
-
|
DE
|
|
|
- |
-
|
DE
|
|
|
- |
-
|
JP
|
|
|
- |
-
|
CH
|
|
|
$6.61B |
-
|
IN
|
